Marshall Wace, LLP Pliant Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 53,880 shares of PLRX stock, worth $185,347. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,880Holding current value
$185,347% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$20.5 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$17.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$15.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$11.1 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$11 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $167M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...